{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:54:23Z","timestamp":1793332463179,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02363848, and RC2017-2019"],"award-info":[{"award-number":["GR-2016-02363848, and RC2017-2019"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine can manifest with an episodic or a chronic pattern in a continuum of disease severity. Multiple factors are associated with the progression of the pattern from episodic to chronic. One of the most consistently reported factors is the overuse of medications (MO) for the acute treatment of migraine attacks. The mechanisms through which MO facilitates the transformation of episodic migraine (EM) into chronic migraine (CM) are elusive. In order to provide insights into these mechanisms, the present study aims to identify possible peripheral biomarkers associated with the two forms of migraine, and with the presence of MO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated the plasma levels of calcitonin gene-related peptide (CGRP) and the expression of miR-34a-5p and miR-382-5p in peripheral blood mononuclear cells of subjects with EM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927) or CM-MO (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928). Subjects in the CM-MO group were also tested 2\u2009months after an in-hospital detoxification protocol.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CGRP, miR-382-5p, and miR-34a-5p levels were significantly higher in CM-MO subjects when compared to EM patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 for all comparisons). After correcting for age, sex, and disease duration, miRNAs expression was still significantly associated with migraine phenotype (EM vs. CM-MO:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014 for miR-382-5p,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038 for miR-34a-5p), while CGRP levels were not (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.115). CGRP plasma levels significantly and positively correlated with miR-382-5p (Spearman\u2019s rho: 0.491,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and miR-34a-5p (Spearman\u2019s rho: 0.303,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=0.025)\u00a0in the overall population. In the CM-MO group, detoxification significantly decreased CGRP levels and miRNAs expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). When comparing responders and non-responders to the detoxification, the former group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) showed significantly higher levels of CGRP at baseline, and significantly lower expression of miR-382-5p after the detoxification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identify a potential panel of peripheral markers associated with migraine subtypes and disease severity. CGRP levels as well as miRNAs expression were influenced by MO, and modulated by detoxification in subjects with CM-MO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The study protocol was registered at www.clinicaltrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04473976?term=NCT04473976&amp;draw=2&amp;rank=1\">NCT04473976<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-020-01189-0","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:02:52Z","timestamp":1602820972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?"],"prefix":"10.1186","volume":"21","author":[{"given":"Rosaria","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9415-4948","authenticated-orcid":false,"given":"Roberto","family":"De Icco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Demartini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Zanaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tumelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Allena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"9","key":"1189_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"HC Diener","year":"2019","unstructured":"Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T (2019) Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 18(9):891\u2013902. https:\/\/doi.org\/10.1016\/S1474-4422(19)30146-2","journal-title":"Lancet Neurol"},{"issue":"5","key":"1189_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/0333102419883355","volume":"40","author":"J Xu","year":"2020","unstructured":"Xu J, Kong F, Buse DC (2020) Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia. 40(5):503\u2013516. https:\/\/doi.org\/10.1177\/0333102419883355","journal-title":"Cephalalgia."},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J HeadachePain 18:101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J HeadachePain"},{"issue":"9","key":"1189_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/0333102414521508","volume":"34","author":"C Tassorelli","year":"2014","unstructured":"Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z, Lainez M, Leston J, Fadic R, Spadafora S, Pagani M, Nappi G, the COMOESTAS consortium (2014) A consensus protocol for the management of medication-overuse headache: evaluationin a multicentric, multinational study. Cephalalgia. 34(9):645\u2013655. https:\/\/doi.org\/10.1177\/0333102414521508","journal-title":"Cephalalgia."},{"issue":"1","key":"1189_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1129-2377-14-10","volume":"14","author":"P Rossi","year":"2013","unstructured":"Rossi P, Faroni JV, Tassorelli C, Nappi G (2013) Advice alone versus structureddetoxification programmes for complicated medication overuse headache (MOH): aprospective, randomized, open-label trial. J Headache Pain 14(1):10. https:\/\/doi.org\/10.1186\/1129-2377-14-10","journal-title":"J Headache Pain"},{"issue":"7","key":"1189_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102411402367","volume":"31","author":"ID Meng","year":"2011","unstructured":"Meng ID, Dodick D, Ossipov MH, Porreca F (2011) Pathophysiology of medicationoveruse headache: insights and hypotheses from preclinical studies. Cephalalgia 31(7):851\u2013860. https:\/\/doi.org\/10.1177\/0333102411402367","journal-title":"Cephalalgia"},{"issue":"3","key":"1189_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/WCO.0b013e328346af25","volume":"24","author":"M De Felice","year":"2011","unstructured":"De Felice M, Ossipov MH, Porreca F (2011) Persistent medication-induced neuraladaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol 24(3):193\u2013196. https:\/\/doi.org\/10.1097\/WCO.0b013e328346af25","journal-title":"Curr Opin Neurol"},{"key":"1189_CR8","doi-asserted-by":"publisher","unstructured":"Greco R, Demartini C, Zanaboni A, Tumelero E, De Icco R, Sances G, Allena M, Tassorelli C (2020) Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: a pilot study. Cephalalgia. https:\/\/doi.org\/10.1177\/0333102420949201","DOI":"10.1177\/0333102420949201"},{"key":"1189_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/j.1526-4610.2012.02170.x","volume":"52","author":"A Perrotta","year":"2012","unstructured":"Perrotta A, Arce-Leal N, Tassorelli C, Gasperi V, Sances G, Blandini F, Serrao M, Bolla M, Pierelli F, Nappi G, MacCarrone M, Sandrini G (2012) Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 52:1350\u20131361","journal-title":"Headache."},{"issue":"3","key":"1189_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ana.21897","volume":"67","author":"M De Felice","year":"2010","unstructured":"De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, Dodick DW, Vanderah TW, Dussor G, Porreca F (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67(3):325\u2013337. https:\/\/doi.org\/10.1002\/ana.21897","journal-title":"Ann Neurol"},{"issue":"4","key":"1189_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/14728214.2018.1552939","volume":"23","author":"G Lambru","year":"2018","unstructured":"Lambru G, Andreou AP, Guglielmetti M, Martelletti P (2018) Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs 23(4):301\u2013318. https:\/\/doi.org\/10.1080\/14728214.2018.1552939","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"1189_CR12","doi-asserted-by":"publisher","first-page":"9367","DOI":"10.3892\/mmr.2017.7779","volume":"16","author":"T Deng","year":"2017","unstructured":"Deng T, Yang L, Zheng Z, Li Y, Ren W, Wu C, Guo L (2017) Calcitonin gene-related peptide induces IL-6 expression in RAW264.7 macrophages mediated by mmu_circRNA_007893. Mol Med Rep 16(6):9367\u20139374. https:\/\/doi.org\/10.3892\/mmr.2017.7779","journal-title":"Mol Med Rep"},{"issue":"1","key":"1189_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/2211536606666170104130101","volume":"6","author":"L Gallelli","year":"2017","unstructured":"Gallelli L, Siniscalchi A, Carotenuto M, Caroleo MC, Cione E, Guidetti V (2017) microRNAs-based predictor factor in patients with migraine-ischemic stroke. Microrna. 6(1):17\u201321. https:\/\/doi.org\/10.2174\/2211536606666170104130101","journal-title":"Microrna."},{"issue":"6","key":"1189_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40291-019-00428-8","volume":"23","author":"P Gazerani","year":"2019","unstructured":"Gazerani P (2019) Current evidence on potential uses of MicroRNA biomarkers for migraine: from diagnosis to treatment. Mol Diagn Ther 23(6):681\u2013694. https:\/\/doi.org\/10.1007\/s40291-019-00428-8","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"1189_CR15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s12035-015-9106-5","volume":"53","author":"HH Andersen","year":"2016","unstructured":"Andersen HH, Duroux M, Gazerani P (2016) Serum MicroRNA signatures in migraineurs during attacks and in pain-free periods. Mol Neurobiol 53(3):1494\u20131500. https:\/\/doi.org\/10.1007\/s12035-015-9106-5","journal-title":"Mol Neurobiol"},{"issue":"34","key":"1189_CR16","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.2174\/0929867325666180622122938","volume":"26","author":"P Ferroni","year":"2019","unstructured":"Ferroni P, Barbanti P, Spila A, Fratangeli F, Aurilia C, Fofi L, Egeo G, Guadagni F (2019) Circulating biomarkers in migraine: new opportunities for precision medicine. Curr Med Chem 26(34):6191\u20136206","journal-title":"Curr Med Chem"},{"key":"1189_CR17","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"issue":"14","key":"1189_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Moroll\u00f3n","year":"2013","unstructured":"Cernuda-Moroll\u00f3n E, Larrosa D, Ram\u00f3n C, Vega J, Mart\u00ednez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 81(14):1191\u20131196. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a6cb72","journal-title":"Neurology."},{"issue":"12","key":"1189_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v050.i12","volume":"50","author":"K Noguchi","year":"2012","unstructured":"Noguchi K, Gel YR, Brunner E, Konietschke F (2012) nparLD : an R software package for the nonparametric analysis of longitudinal data in factorial experiments. J Stat Softw 50(12):1\u201323. https:\/\/doi.org\/10.18637\/jss.v050.i12","journal-title":"J Stat Softw"},{"issue":"5","key":"1189_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener H-C, Dodick DW et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia."},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"AF Russo","year":"2015","unstructured":"Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533\u2013552. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124701","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"1189_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-020-01134-1","volume":"21","author":"JCA Edvinsson","year":"2020","unstructured":"Edvinsson JCA, Vigan\u00f2 A, Alekseeva A, Alieva E, Arruda R, De Luca C, D'Ettore N, Frattale I, Kurnukhina M, Macerola N, Malenkova E, Maiorova M, Novikova A, \u0158ehulka P, Rapaccini V, Roshchina O, Vanderschueren G, Zvaune L, Andreou AP, Haanes KA, European Headache Federation School of Advanced Studies (EHF-SAS) (2020) The fifth cranial nerve in headaches. J Headache Pain 21(1):65. https:\/\/doi.org\/10.1186\/s10194-020-01134-1","journal-title":"J Headache Pain"},{"issue":"1","key":"1189_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-018-0848-0","volume":"19","author":"K Messlinger","year":"2018","unstructured":"Messlinger K (2018) The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain 19(1):22. https:\/\/doi.org\/10.1186\/s10194-018-0848-0","journal-title":"J Headache Pain"},{"issue":"3","key":"1189_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/WCO.0000000000000440","volume":"30","author":"C Ram\u00f3n","year":"2017","unstructured":"Ram\u00f3n C, Cernuda-Moroll\u00f3n E, Pascual J (2017) Calcitonin gene-related peptide peripheral blood as a biomarker for migraine. Curr Opin Neurol 30(3):281\u2013286. https:\/\/doi.org\/10.1097\/WCO.0000000000000440","journal-title":"Curr Opin Neurol"},{"key":"1189_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.peptides.2019.04.012","volume":"116","author":"G Tringali","year":"2019","unstructured":"Tringali G, Navarra P (2019) Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 116:16\u201321. https:\/\/doi.org\/10.1016\/j.peptides.2019.04.012","journal-title":"Peptides."},{"key":"1189_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.nbd.2014.08.003","volume":"71","author":"HH Andersen","year":"2014","unstructured":"Andersen HH, Duroux M, Gazerani P (2014) MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions. Neurobiol Dis 71:159\u2013168. https:\/\/doi.org\/10.1016\/j.nbd.2014.08.003","journal-title":"Neurobiol Dis"},{"issue":"12","key":"1189_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/mp.2011.58","volume":"16","author":"MD Li","year":"2011","unstructured":"Li MD, van der Vaart AD (2011) MicroRNAs in addiction: adaptation\u2019s middlemen? Mol Psychiatry 16(12):1159\u20131168. https:\/\/doi.org\/10.1038\/mp.2011.58","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1189_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-018-0883-x","volume":"19","author":"MJ Lee","year":"2018","unstructured":"Lee MJ, Lee SY, Cho S, Kang ES, Chung CS (2018) Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 19(1):53. https:\/\/doi.org\/10.1186\/s10194-018-0883-x","journal-title":"J Headache Pain"},{"issue":"3","key":"1189_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/ane.13053","volume":"139","author":"SB Munksgaard","year":"2019","unstructured":"Munksgaard SB, Ertsey C, Frandsen E, Bendtsen L, Tekes K, Jensen RH (2019) Circulating nociceptin and CGRP in medication-overuse headache. Acta Neurol Scand 139(3):269\u2013275. https:\/\/doi.org\/10.1111\/ane.13053","journal-title":"Acta Neurol Scand"},{"key":"1189_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fneur.2019.00010","volume":"10","author":"PC Fan","year":"2019","unstructured":"Fan PC, Kuo PH, Lee MT, Chang SH, Chiou LC (2019) Plasma calcitonin gene-related peptide: a potential biomarker for diagnosis and therapeutic responses in pediatric migraine. Front Neurol 10:10. https:\/\/doi.org\/10.3389\/fneur.2019.00010","journal-title":"Front Neurol"},{"key":"1189_CR31","doi-asserted-by":"publisher","unstructured":"Frederiksen SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, Edvinsson L (2020) Serotonin and neuropeptides in blood from episodic and chronic migraine and cluster headache patients in case-control and case-crossover settings: a systematic review and meta-analysis. Headache. 15. https:\/\/doi.org\/10.1111\/head.13802","DOI":"10.1111\/head.13802"},{"key":"1189_CR32","doi-asserted-by":"publisher","first-page":"333102420942230","DOI":"10.1177\/0333102420942230","volume":"26","author":"R De Icco","year":"2020","unstructured":"De Icco R, Fiamingo G, Greco R, Bottiroli S, Demartini C, Zanaboni AM, Allena M, Guaschino E, Martinelli D, Putort\u00ec A, Grillo V, Sances G, Tassorelli C (2020) Neurophysiological and biomolecular effects of erenumab in chronic migraine: an open label study. Cephalalgia. 26:333102420942230. https:\/\/doi.org\/10.1177\/0333102420942230","journal-title":"Cephalalgia."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01189-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:49:15Z","timestamp":1634330955000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01189-0","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"18 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Ethics Committee (N\u00b0 p-20170023682) and all subjects enrolled signed at T0 a written informed consent, in accordance with the Declaration of Helsinki and existing national ethics regulation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CT received honoraria for the participation to advisory boards or for oral presentations from: Allergan, ElectroCore, Eli-Lilly, Novartis, and Teva. CT has no ownership interest and does not own stocks of any pharmaceutical company. CT serves as Chief Section Editor of Frontiers in Neurology\u2014Section Headache Medicine and Facial Pain and on the editorial board of The Journal of Headache and Pain. GS received honoraria for the participation to advisory boards or for oral presentations from: Eli-Lilly and Novartis. The remaining authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}